Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Education Catalog

  • Sickle Cell Disease: Exploring treatment options and psychosocial care
  • Continuing Education Discontinuation
  • Building Yourself From The Ground Up
  • Resources and Education
  • Education Catalog
  • AML & MDS: Older Patients
  • Email
  • Print This Page

AML & MDS: Older Patients

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

 Access Course
(Medscape requires a one-time free registration to access the activity)

Description

Explore practical applications of classification and research data to compare treatment choices for older AML and MDS patients, including:

  • How diagnostic testing has changed the timing of therapeutic choices and if age should be considered
  • Applying data to mitigate risk and optimize the benefit among new drugs, transplantation, and combination approaches
  • What coverage options are available for Medicare-eligible patients

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Learning Objectives

  1. Identify disease- and patient-related factors that predict outcomes of hematopoietic cell transplantation (HCT), new drugs, or combination therapy in older patients with MDS and AML
  2. Explain recent clinical trial results that have influenced the selection of patients in trials for treatment of MDS and AML.
  3. Compare the risks and benefits of treatment options and how timing of therapy choices affects outcomes
  4. Describe appropriate candidates for a prospective study on outcomes of HCT in adults 65 years of age and older with MDS

Faculty

  • Frederick R. Appelbaum, M.D.
    Executive Director, Seattle Cancer Care Alliance; Director, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine, Seattle, Washington
  • Stephen J. Forman, M.D.
    Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation; Clinical Director, Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, California
  • Gail J. Roboz, M.D.
    Director, Leukemia Program; Associate Professor of Medicine, Weill Medical College, Cornell University, New York, New York.
  • David Steensma, M.D.
    Associate Professor of Medicine, Harvard Medical School; Adult Leukemia Program, Dana-Farber Cancer Institute; Hematological Oncology Service, Brigham & Women’s Hospital, Boston, Massachusetts
  • Willis Navarro, M.D.
    Vice President, Transplant Medical Services, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

 Questions

If you have any questions regarding this activity or for assistance for people with disabilities, grievances, please email nmdpeducation@nmdp.org. 

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2021 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright